Multiple sclerosis

Physical Management in Neurological Rehabilitation

Volumn , Issue , 2004, Pages 177-201

  De Souza, Lorraine ^a   Bates, David ^b  

^a BRUNEL UNIVERSITY   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77954962411     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-072343285-2.50014-0     Document Type: Chapter

References (108)

1. Alexander J, Costello E Physical and surgical therapy. Multiple Sclerosis: A Guide for Patients and their Families 1987, 79-107. Raven Press, New York. 2nd edn. L.C. Scheinberg, N.J. Holland (Eds.).
2. Armutlu K, Karabudak R, Nurlu G Physiotherapy approaches in the treatment of ataxic multiple sclerosis: a pilot study. Neurorehab Neural Repair 2001, 15:203-211.
3. Arndt J, Bhasin C, et al. Physical therapy. Multiple Sclerosis: A Rehabilitation Approach to Management 1991, 17-66. Demos, New York. S.P. Brar, R.T. Schapiro (Eds.).
4. Ashburn A, De Souza LH An approach to the management of multiple sclerosis. Physiother Pract 1988, 4:139-145.
5. Barnes M Multiple sclerosis. Neurological Rehabilitation 1993, 485-504. Churchill Livingstone, London. R. Greenwood, M.P. Barnes, T.M. McMillan (Eds.).
6. Beck RW, Cleary PA, Trobe JD, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 1993, 329:1764-1769.
7. Blackford KA Strategies for intervention and research with children or adolescents who have a parent with multiple sclerosis. Axon 1992, Dec:50-55.
8. Block JM, Kester NC The role of rehabilitation in the management of multiple sclerosis. Modern Treat 1970, 7(5).
9. Brandt T, Krafczyk S, Malsbenden J Postural imbalance with head extension: improvement by training as a model for ataxia therapy. Ann NY Acad Sci 1981, 374:636-649.
10. Brandt T, Buchele W, Krafczyk S Training effects on experimental postural instability: a model for clinical ataxia therapy. Disorders of Posture and Gait 1986, 353-365. Elsevier, Amsterdam. W. Bles, T. Brandt (Eds.).
11. Burnfield A Multiple Sclerosis: A Personal Exploration 1985, Souvenir Press, London.
12. Burnfield A, Frank A Multiple sclerosis. Disabling Diseases - Physical, Environmental and Psychosocial Management 1988, Heinemann Medical, London. A. Frank, P. Maguire (Eds.).
13. Compston DAS Distribution of multiple sclerosis. McAlpine's Multiple Sclerosis 2000, 63-100. Churchill Livingstone, New York. 3rd edn. A. Compston, G. Ebers, H. Lussmann (Eds.).
14. Corboy JR, Goodin DS, Frohman EM Disease-modifying therapies for multiple sclerosis. Curr Treat Options Neurol 2003, 5:35-54.
15. Cornish CJ, Mattision PG Symptom management in advanced multiple sclerosis. CME Bull Palliative Med 2000, 2:11-16.
16. Costello E, Curtis CL, Sandel IB, et al. Exercise prescription for individuals with multiple sclerosis. Neurol Rep 1996, 20:24-30.
17. DasGupta R, Fowler CJ Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies. Drugs 2003, 63:153-166.
18. De Souza LH A different approach to physiotherapy for multiple sclerosis patients. Physiotherapy 1984, 70:429-432.
19. De Souza LH Multiple Sclerosis: Approaches to Management 1990, Chapman & Hall, London.
20. De Souza LH Physiotherapy. Rehabilitation of the Physically Disabled Adult 1997, 560-575. Chapman & Hall, London. 2nd edn. J. Goodwill, M.A. Chamberlain, C. Evans (Eds.).
21. De Souza LH, Worthington JA The effect of long-term physiotherapy on disability in multiple sclerosis patients. Multiple Sclerosis: Immunological, Diagnostic and Therapeutic Aspects 1987, 155-164. John Libbey, London. F. Clifford Rose, R. Jones (Eds.).
22. Dean G, Kurtzke JF On the risk of multiple sclerosis according to the age at immigration to South Africa. Br Med J 1971, 3:725-729.
23. Di Fabio RP, Choi T, Soderberg J, et al. Health related quality of life for patients with progressive multiple sclerosis: influence of rehabilitation. Phys Ther 1997, 77:1704-1716.
24. Di Fabio RP, Soderberg J, Choi T, et al. Extended outpatient rehabilitation: its influence on symptoms frequency, fatigue and functional status for persons with progressive multiple sclerosis. Arch Phys Med Rehab 1998, 79:141-146.
25. Ebers GC, Bulman DE, Sadovnick AD A population-based study of multiple sclerosis in twins. N Engl J Med 1986, 315:1638-1642.
26. Placebo controlled multi-centre randomised trial of interferon b-1b in the treatment of secondary progressive multiple sclerosis. Lancet 1998, 352:1491-1497. European Study Group on Interferon b-1b in Secondary Progressive Multiple Sclerosis.
27. Fassas A, Deconinck E, Musso M, et al. Haematopoietic stem cell transplantation for multiple sclerosis; a retrospective multi centre study. J Neurol 2002, 249:1088-1094.
28. Filippi M, Horsefield MA, Ader HJ, et al. Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis. Ann Neurol 1998, 43:499-506.
29. Fisk JD, Pontefract A, Ritvo PG, et al. The impact of fatigue on multiple sclerosis. Can J Neurol Sci 1994, 21:9-14.
30. Forsythe E Multiple Sclerosis: Exploring Sickness and Health 1988, Faber & Faber, London.
31. Freal JE, Kraft GH, Coryell JK Symptomatic fatigue in multiple sclerosis. Arch Phys Med Rehab 1984, 65:135-138.
32. Standards of Healthcare for People with MS 1997, Multiple Sclerosis Society, London. J. Freeman, J. Johnson, S. Rollinson (Eds.).
33. Freeman JA, Lagndon DW, Hobart JC, et al. The impact of inpatient rehabilitation on progressive multiple sclerosis. Ann Neurol 1997, 42:236-244.
34. Freeman JA, Lagndon DW, Hobart JC, et al. Inpatient rehabilitation: do the benefits carry over into the community?. Neurology 1999, 52:50-56.
35. Developing MS Healthcare Standards. The MS Society 2001, Multiple Sclerosis Society, London. J. Freeman, H. Ford, P. Mattison (Eds.).
36. Ghalie RG, Edan G, Laurent M, et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002, 59:909-913.
37. Ghalie RG, Mauch E, Edan G, et al. A study of therapy-realted acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 2002, 8:441-445.
38. Goodin DS, Frohman EM, Garmany GP Disease modifying therapies in multiple sclerosis: report of the therapeutics and technology assessments sub-committee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002, 58:169-178.
39. Goodkin DE, Rudick PS, Vanderbrug Medendorp S, et al. Low dose (7.5mg) oral methotrexate reduces the rate of progression of chronic progressive multiple sclerosis. Ann Neurol 1995, 37:30-40.
40. Greenspun B, Stineman M, Agri R Multiple sclerosis and rehabilitation outcome. Arch Phys Med Rehab 1987, 68:434-437.
41. Halliday AM, McDonald WI Pathophysiology of demyelinating disease. Br Med Bull 1977, 33:21-27.
42. Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002, 360:2018-2025.
43. Holmes J, Madgwick T, Bates D The cost of multiple sclerosis. Br J Med Economics 1995, 8:181-193.
44. Hulter BM, Lundberg OL Sexual function in women with advanced multiple sclerosis. J Neurol Neurosurg Psychiatry 1995, 59:83-86.
45. IFBN Multiple Sclerosis Study Group Interferon b-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of multicentre, randomised, double-blind, placebo-controlled trial. Neurology 1993, 43:655-661.
46. Ingle GT, Stevenson VL, Miller DH, et al. Two year follow-up study of primary and transitional progressive multiple sclerosis. Multiple Sclerosis 2002, 8:108-114.
47. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon b-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996, 39:285-294.
48. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer-1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multi-centre, double blind, placebo controlled trial. Neurology 1995, 45:1268-1276.
49. Klaus L Diet and multiple sclerosis. Neurology 1997, 49(Suppl. 2):S55-S61.
50. Ko Ko C Effectiveness of rehabilitation for multiple sclerosis. Clin Rehab 1999, 13(Suppl. 1):33-41.
51. Krupp LB, Alvarez LA, LaRocca NG, et al. Fatigue in multiple sclerosis. Arch Neurol 1988, 45:435-437.
52. Krupp LB, La Rocca NG, Muir-Nash J, et al. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989, 46:1121-1123.
53. Kurtzke JF Rating neurological impairment in multiple sclerosis: an expanded disability scale, (EDSS). Neurology 1983, 33:1444-1452.
54. Kurtzke JF, Hyllested K Multiple sclerosis in the Faroe Islands: II. Clinical update, transmission and the nature of MS. Neurology 1986, 36:307-312.
55. Langton Hewer R The epidemiology of disabling neurological disorders. Neurological Rehabilitation 1993, 3-12. Churchill Livingstone, London. R. Greenwood, M.P. Barnes, T.M. McMillan (Eds.).
56. Lenman JAR, Tulley FM, Vrbov G, et al. Muscle fatigue in some neurological conditions. Muscle Nerve 1989, 12:938-942.
57. Lord SE, Wade DT, Halligan PW A comparison of two physiotherapy treatment approaches to improve walking in multiple sclerosis: a pilot randomised controlled study. Clin Rehab 1998, 12:477-486.
58. Loseff NA, Wang L, Lai HM, et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 1996, 19:2009-2019.
59. Lucchinetti CF, Bruek W, Rodriguez M, et al. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol 1996, 66:259-274.
60. Matthews WB Symptoms and signs in multiple sclerosis. McAlpine's Multiple Sclerosis 1985, Churchill Livingstone, Edinburgh. W.B. Matthews, E.D. Acheson, J.R. Batchelor, R.O. Weller (Eds.).
61. Matthews WB, Acheson ED, Batchelor JR, et al. McAlpine's Multiple Sclerosis 1991, Churchill Livingstone, Edinburgh. 2nd edn.
62. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel for the Diagnosis of Multiple Sclerosis. Ann Neurol 2001, 50:121-127.
63. McQueen Davis ME, Niskala H Nurturing a valuable resource: family caregivers in multiple sclerosis. Axon 1992, March:87-91.
64. Misulis KE Essentials of Clinical Neurophysiology 1993, Butterworth Heinemann, London.
65. Moreau T, Thorpe J, Miller D, et al. Reduction in new lesion formation in multiple sclerosis following lymphocyte depletion with CAMPATH-1H. Lancet 1994, 344:298-301.
66. Morgan MH Ataxia - its causes, measurement and management. Int Rehab Med 1980, 2:126-132.
67. Mostert S, Kesselring J Effects of a short-term exercise training program on aerobic fitness, fatigue, health perception and activity level of subjects with multiple sclerosis. Multiple Sclerosis 2002, 8:161-168.
68. O'Brien B. Multiple Sclerosis. Office of Health Economics Publications no 87. London: 1987.
69. O'Connor P Key issues in the diagnosis and treatment of multiple sclerosis. An overview. Neurology 2002, 59(Suppl. 3):S1-S33.
70. Odeen I Reduction of muscular hypertonus by long-term muscle stretch. Scand J Rehab Med 1981, 13:93-99.
71. O'Hara L, De Souza LH, Ide L A delphi study of self-care in a community population of people with multiple sclerosis. Clin Rehab 2000, 14:62-71.
72. O'Hara L, Cadbury H, De Souza L, et al. Evaluation of the effectiveness of professionally guided self-care for people with multiple sclerosis living in the community: a randomised controlled trial. Clin Rehab 2002, 16:119-128.
73. Oliver MJ Social Work with Disabled People 1983, Macmillan Press, London.
74. Page WF, Kurtzke JF, Murphy FM, et al. Epidemiology of multiple sclerosis in US veterans: ancestry and the risk of multiple sclerosis. Ann Neurol 1993, 33:632-639.
75. Paty DW, Li DKB The UCB MS/MRI study group and the IFNB multiple sclerosis study group. Interferon b-1b is effective in relapsing remitting multiple sclerosis II MRI results in a multi-centre randomised, double blind, placebo controlled trial. Neurology 1993, 43:663-667.
76. Paty DW, Oger JJF, Kastrukoff LF, et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding and CT. Neurology 1988, 38:180-185.
77. Payne A Nutrition and diet in the clinical management of multiple sclerosis. J Hum Nutr Dietet 2001, 14:349-357.
78. Petajan JH, Gappmaier E, White AT, et al. Impact of aerobic fitness and quality of life in multiple sclerosis. Ann Neurol 1996, 39:432-441.
79. Ponichtera-Mulcare JA, Matthews T, Barrett G, et al. Change in aerobic fitness of patients with multiple sclerosis during 6-month training program. Sports Med Train Rehab 1997, 7:265-272.
80. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983, 13:227-231.
81. Poser S, Kurtzke JF, Schaff G Survival in multiple sclerosis. J Clin Epidemiol 1989, 42:159-168.
82. Prineas JW, Connell F The fine structure of chronically active multiple sclerosis plaques. Neurology 1978, 28:68-75.
83. PRISMS study group Randomised double blind, placebo controlled study of interferon b-1a in relapsing/remitting multiple sclerosis. Lancet 1998, 352:1498-1504.
84. Rao SM, Cognitive Function Study Group A Manual for the Brief Repeatable Battery of Neuropsychological Tests in Multiple Sclerosis 1990, National MS Society, New York.
85. Rodgers MM, Mulcare JA, King DL, et al. Gait characteristics of individuals with multiple sclerosis before and after a 6-month aerobic training program. J Rehab Res Dev 1999, 36:183-188.
86. Rosche J, Rub K, Niemann-Delius B, et al. Effects of physiotherapy on F-wave amplitudes in spasticity. Electromyogr Clin Neurophysiol 1996, 36:509-511.
87. Russell WR, Palfrey G Disseminated sclerosis: rest-exercise therapy - a progress report. Physiotherapy 1969, 55:306-310.
88. Scheinberg LC Introduction. Multiple Sclerosis: A Guide for Patients and their Families 1987, 1-2. Raven Press, New York. 2nd edn. L.C. Scheinberg, N.J. Holland (Eds.).
89. Scolding N The differential diagnosis of multiple sclerosis. J Neurol Neurosurg Psychiatry 2001, 71(Suppl.):9-15.
90. Segal J, Simpkins J 'My Mum Needs Me': Helping Children with Ill or Disabled Parents 1993, Penguin Books, London.
91. Shepherd GM Neurobiology 1994, Oxford University Press, New York.
92. Sibley W Therapeutic Claims in Multiple Sclerosis 1988, 104. Demos, New York.
93. Snow BJ, Tsui JKC, Bhatt MH, et al. Treatment of spasticity with botulinum toxin: a double blind study. Ann Neurol 1990, 28:512-515.
94. Soderberg J MS and the family system. Multiple Sclerosis and the Family. 1992, 1-7. Demos, New York. R. Kalb, L.C. Scheinberg (Eds.).
95. Solari A, Filipini G, Gasro P, et al. Physical rehabilitation has a positive effect on disability in multiple sclerosis patients. Neurology 1999, 52:57-69.
96. Spackman AJ, Doulton DC, Roberts MHW, et al. Caring at night for people with multiple sclerosis. BMJ 1989, 299:1433.
97. Tallis RC, Illis LS, Sedgwick EM The quantitative assessment of the influence of spinal cord stimulation on motor function in patients with multiple sclerosis. Int J Rehab Med 1983, 5:10-16.
98. Tantacci G, Massucci M, Piperno R, et al. Energy cost of exercise in multiple sclerosis patients with low degree of disability. Multiple Sclerosis 1996, 2:161-167.
99. Thompson AJ Symptomatic management and rehabilitation in multiple sclerosis. J Neurol Neurosurg Psychiatry 2001, 71(Suppl. 2):ii22-ii27.
100. Todd J Physiotherapy in multiple sclerosis. Progress in Rehabilitation: Multiple Sclerosis 1982, 31-44. Macmillan Press, London. R. Capildeo, A. Maxwell (Eds.).
101. Todd J Multiple sclerosis - management. Cash's Textbook of Neurology for Physiotherapists 1986, 398-416. Faber & Faber, London. 4th edn. P.A. Downie (Ed.).
102. Tourtellotte WW, Booe IM Multiple sclerosis: the blood-brain barrier and the measurement of de novo central nervous system IgG synthesis. Neurology 1978, 28(Suppl.):76-82.
103. Trapp PD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998, 338:278-285.
104. Wiles C, Newcombe RG, Fuller KJ, et al. A controlled randomised crossover trial of the effects of physiotherapy on mobility in chronic multiple sclerosis. J Neurol Neurosurg Psychiatry 2001, 70:174-179.
105. Williams G Disablement and the social context of daily activity. Int Disabil Stud 1987, 9:97-102.
106. Worthington JA, De Souza LH The use of clinical measures in the evaluation of neuromuscular stimulation in multiple sclerosis patients. Current Concepts in Multiple Sclerosis 1990, 213-218. Elsevier, London. H. Wientholter, J. Dichgans, J. Mertin (Eds.).
107. McAlpine's Multiple Sclerosis 1998, Churchill Livingstone, London. 3rd edn. A. Compston, G. Ebers, H. Lassman (Eds.).
108. Multiple Sclerosis 1997, EA Davis, Philadelphia. D.W. Paty, G.C. Ebers (Eds.).